Opinion: Purple Book Patent Listings Are Only a First Step
May 8, 2021
By: Ted Mathias and Aaron Savit, PhD
The Center for Biosimilars
Axinn partners Ted Mathias and associate Aaron Savit authored The Center for Biosimilars article, "Opinion: Purple Book Patent Listings Are Only a First Step."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IBA Annual Conference 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Antitrust 101: Trial-Minded Antitrust Discovery
Webinar
Antitrust
ABA Antitrust Plaintiffs' Roundtable 2025
Speaking Engagement
Antitrust
Centerforce IP Strategy Summit: Palo Alto
Speaking Engagement
Intellectual Property
Who Is Elizabeth Odette? Meet the Chair of NAAG’s Multistate Antitrust Task Force
Podcast